ENTOD Pharmaceuticals has gained approval from the Central Drugs Standard Control Organisation (CDSCO) for PresVu to treat age-related vision impairment.

According to the company’s statement, PresVu is a revolutionary Treatment for presbyopia which is the gradual loss of your eyes’ ability to focus on nearby objects.

The company claims that it is a first-of-its-kind eye drop in India and it can alleviate the need for reading glasses among individuals grappling with the condition.

Presbyopia, characterized by blurred near vision due to the decreased flexibility of the eye’s natural lens, primarily impacts individuals aged 40 and above.

“With PresVu, ENTOD Pharmaceuticals introduces a game-changing intervention, offering swift relief and temporary correction of vision problems associated with presbyopia. Leveraging innovative dynamic buffer technology developed through their DSIR-approved R&D facility, PresVu eye drops adjust rapidly to tear pH, ensuring sustained efficacy and safety for long-term use,” the company said in a statement.

The company completed the development of these eye drops in late 2022 after which it was subjected to clinical testing in India. Phase 3 clinical trials carried out in India and the US have demonstrated PresVu’s efficacy in enhancing close-up vision within minutes of application, with effects lasting up to six hours, it claimed.

This groundbreaking formulation holds immense promise for individuals aged 40 to 55 with mild to intermediate presbyopia, providing a viable alternative to traditional interventions like reading glasses, it stated.

“The approval of PresVu represents a significant breakthrough in our mission to redefine eye care in India. As the innovator in presbyopia treatment in India, we aim to empower individuals to regain visual clarity and independence, free from the constraints of reading glasses. As part of our commitment to ‘Make in India,’ we are dedicated to manufacturing PresVu eye drops at an affordable price, ensuring accessibility to all segments of society,” Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, said in a statement.